Last Updated : December 11, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Celsentri | Maraviroc | HIV | List with clinical criteria and/or conditions | Complete | ||
Cerdelga | Eliglustat | Gaucher disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Champix | Varenicline tartrate | Smoking-cessation | List with clinical criteria and/or conditions | Complete | ||
Cibinqo | abrocitinib | Atopic dermatitis, moderate to severe | Reimburse with clinical criteria and/or conditions | Complete | ||
Cimzia | certolizumab pegol | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | ||
Cimzia | Certolizumab pegol | Arthritis, rheumatoid | Do not list | Complete | ||
Cimzia | Certolizumab pegol | Ankylosing spondylitis | List with criteria/condition | Complete | ||
Cimzia | Certolizumab pegol | Arthritis, psoriatic | List with criteria/condition | Complete | ||
Cinqair | reslizumab | Asthma, eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
Cinqair | Reslizumab | Asthma, eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
Cipralex | Escitalopram oxalate | Depression, Major Depressive Disorder (MDD) | Withdrawn | |||
Cipralex | Escitalopram oxalate | Depression, Major Depressive Disorder (MDD) | Do not list | Complete | ||
Ciprodex | Ciprofloxacin hydrochloride and dexamethasone otic suspension | Otitis media with otorrhea & otitis externa, acute | Do not list | Complete | ||
Ciprodex | Ciprofloxacin hydrochloride & dexamethasone otic suspension | Otitis media with otorrhea & otitis externa, acute | List with clinical criteria and/or conditions | Complete | ||
Clolar | clofarabine | Acute lymphoblastic leukemia | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | ||
Columvi | glofitamab | Relapsed or refractory diffuse large B-cell lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Combigan Ophthalmic Solution | Brimonidine tartrate/timolol maleate | Glaucoma | List with clinical criteria and/or conditions | Complete | ||
COMPLERA | Emtricitabine/ rilpivirine/ tenofovir disoproxil fumarate | HIV infection | List | Complete | ||
Constella | Linaclotide | Irritable bowel syndrome with constipation | Do not list | Complete | ||
Contrave | naltrexone hydrochloride and bupropion hydrochloride | Chronic weight management in adults | Do not reimburse | Complete | ||
Copaxone | Glatiramer acetate | Clinically Isolated Syndrome (CIS), suggestive of Multiple Sclerosis | Do not list | Complete | ||
Cortiment | Budesonide | Ulcerative Colitis | Do not reimburse | Complete | ||
Corzyna | ranolazine | Stable angina pectoris, adults | Do not reimburse | Complete | ||
Cosentyx | Secukinumab | Plaque psoriasis | List with criteria/condition | Complete | ||
Cosentyx | Secukinumab | ankylosing spondylitis | Reimburse with clinical criteria and/or conditions | Complete |